Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryoko Ihara

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 20, 2025
Real-world lecanemab adoption in Japan 1 year after launch: Insights from 311 specialists on infrastructure and reimbursement barriersKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
The Journal of Prevention of Alzheimer'S Disease|April 12, 2026
ATNIVS biomarker heterogeneity in real-world patients receiving lecanemabMasanori Kurihara, Ryoko Ihara, Gen Yoshii, et al.
Scientific Reports|July 27, 2023
High sensitivity of asymmetric <sup>18</sup>F-THK5351 PET abnormality in patients with corticobasal syndromeMasanori Kurihara, Kenji Ishibashi, Tomoyasu Matsubara, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|June 8, 2026
Clinical and MRI features associated with amyloid positivity in secondary screening for anti-amyloid-β therapyKazuki Yamada, Masanori Kurihara, Yusuke Akitomi, et al.
Neuroimage. Clinical|August 11, 2019
Visualizing modules of coordinated structural brain atrophy during the course of conversion to Alzheimer's disease by applying methodology from gene co-expression analysisKenichiro Sato, Tatsuo Mano, Hiroshi Matsuda, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|March 4, 2023
Correlations between cerebrospinal fluid homovanillic acid and dopamine transporter SPECT in degenerative parkinsonian syndromesRyoji Goto, Masanori Kurihara, Masashi Kameyama, et al.
Journal of Alzheimer'S Disease : JAD|March 1, 2019
Lower Serum Calcium as a Potentially Associated Factor for Conversion of Mild Cognitive Impairment to Early Alzheimer's Disease in the Japanese Alzheimer's Disease Neuroimaging InitiativeKenichiro Sato, Tatsuo Mano, Ryoko Ihara, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 29, 2021
Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort studyKenichiro Sato, Ryoko Ihara, Kazushi Suzuki, et al.
British Journal of Clinical Pharmacology|December 23, 2022
A first-in-human study of the anti-inflammatory profibrinolytic TMS-007, an SMTP family triprenyl phenolTakashi Moritoyo, Naoko Nishimura, Keiko Hasegawa, et al.
Alzheimer'S & Dementia (New York, N. Y.)|December 22, 2025
Immediate reactions to amyloid PET disclosure in Japanese older adults without dementiaKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 20, 2025
Real-world lecanemab adoption in Japan 1 year after launch: Insights from 311 specialists on infrastructure and reimbursement barriersKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
The Journal of Prevention of Alzheimer'S Disease|April 12, 2026
ATNIVS biomarker heterogeneity in real-world patients receiving lecanemabMasanori Kurihara, Ryoko Ihara, Gen Yoshii, et al.
Scientific Reports|July 27, 2023
High sensitivity of asymmetric <sup>18</sup>F-THK5351 PET abnormality in patients with corticobasal syndromeMasanori Kurihara, Kenji Ishibashi, Tomoyasu Matsubara, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|June 8, 2026
Clinical and MRI features associated with amyloid positivity in secondary screening for anti-amyloid-β therapyKazuki Yamada, Masanori Kurihara, Yusuke Akitomi, et al.
Neuroimage. Clinical|August 11, 2019
Visualizing modules of coordinated structural brain atrophy during the course of conversion to Alzheimer's disease by applying methodology from gene co-expression analysisKenichiro Sato, Tatsuo Mano, Hiroshi Matsuda, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|March 4, 2023
Correlations between cerebrospinal fluid homovanillic acid and dopamine transporter SPECT in degenerative parkinsonian syndromesRyoji Goto, Masanori Kurihara, Masashi Kameyama, et al.
Journal of Alzheimer'S Disease : JAD|March 1, 2019
Lower Serum Calcium as a Potentially Associated Factor for Conversion of Mild Cognitive Impairment to Early Alzheimer's Disease in the Japanese Alzheimer's Disease Neuroimaging InitiativeKenichiro Sato, Tatsuo Mano, Ryoko Ihara, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 29, 2021
Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort studyKenichiro Sato, Ryoko Ihara, Kazushi Suzuki, et al.
British Journal of Clinical Pharmacology|December 23, 2022
A first-in-human study of the anti-inflammatory profibrinolytic TMS-007, an SMTP family triprenyl phenolTakashi Moritoyo, Naoko Nishimura, Keiko Hasegawa, et al.
Alzheimer'S & Dementia (New York, N. Y.)|December 22, 2025
Immediate reactions to amyloid PET disclosure in Japanese older adults without dementiaKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
Pageof 6